Abstract 134P
Background
An important proportion of patients receiving PARPi will become resistant. Doxorubicin is one of the drugs used as standard of care in HGSOC becoming resistant to platinum. The ROLANDO trial showed an encouraging activiy in platinum-resistant HGSOC of the combinacion of OLA-Doxo. The aim of our study was to assess if doxorubicin and OLA are synergistic in both PARP-I sensibitve and PARPi- resistant models.
Methods
8 cell lines, 4 parental and 4 corresponding OLA resistant clonal lines were used. One triple-negative breast cancer (TNBC) line (MDA-MB-231) and 3 HGSOC OLA-sensitive cell lines (PEO1, Kuramochi and SKOV3) were acquired. We generated 4 OLA resistant cell lines (MDA-MB-231-R, Kuramochi-R, PEO1-R and SKOV3-R) by exposure to OLA. IC50 of OLA and doxorubicin and the combination of both (combo) were calculated in all 8 lines (sensitive and resistance). Synergism between both drugs was assessed with the Chou Talalay method for combination index (CI) at Fa50. BRCA status (mutation vs wild type (wt)) was assessed by NGS in every line.
Results
When compared with parental lines DOXO IC50 was statistically superior in resistant cell lines except in PEO1-R suggesting a potential cross-resistant between OLA and DOXO. DOXO + OLA were synergistic in both parental and OLA-resistant lines in MDA-MB-231, PEO1 and SKOV3, with Fa50 for resistant lines=0.41 and 0.38 and 0.67 respectively. However, in Kuramochi combo was not synergistic, with Fa 50=1.36. DNA damage assessed by H2AX was similar between combo and DOXO single agent in all parental and resistant lines. Table: 134P
MD231 | MD231R | PEO1 | PEO1R | Kura | KuraR | SKOV3 | SKOV3R | |
BRCA mutation | Wt | Wt | BRCA2 | BRCA2 | BRCA2 | BRCA2 | Wt | Wt |
DOXO IC50 (nM) | 313.3 | 676.2 | 101.2 | 67.3 | 122.6 | 995.3 | 312.1 | 581.5 |
Chou Talalay (Fa 50) | 0.5 | 0.41 | 0.44 | 0.38 | 1.36 | 0.97 | 0.25 | 0.67 |
Conclusions
Our in vitro models suggest that OLA-resistant cells have a cross-resistance to Doxo. However synergistic effect of OLA+DOXO is observed in most OLA-resistant cell lines except in kuramochi-R. Further analyses will confirm whether this combination might be a valuable strategy to overcome OLA-resistance.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
INCLIVA.
Funding
AstraZeneca.
Disclosure
J.A. Perez Fidalgo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Clovis, GSK, PharmaMar, AstraZeneca, Artios Pharma; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Clovis, PharmaMar, Roche, Abilify Pharma; Financial Interests, Personal, Full or part-time Employment, Associate Professor: University of Valencia; Financial Interests, Institutional, Research Grant: GSK, PharmaMar; Financial Interests, Institutional, Invited Speaker: Novartis, AstraZeneca; Financial Interests, Institutional, Funding: GSK; Non-Financial Interests, Personal, Project Lead, Coordinating PI Phase III trial in breast cancer: Novartis; Non-Financial Interests, Personal, Member, Member of the Early Drug Development working group: ENGOT; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and Head of the Scientific Committee: GEICO; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and co-coordinator of Uterine Sarcoma Group: GEIS; Non-Financial Interests, Personal, Leadership Role, Co-chair Phase 2 group: GCIG; Non-Financial Interests, Personal, Member: BIG; Non-Financial Interests, Personal, Member, Adolescent and Young Adults working group: SEOM.M. Mendiola: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Personal, Research Grant: PharmaMar; Financial Interests, Personal, Other: Roche, Pfizer. A. Redondo Sanchez: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Institutional, Invited Speaker: Roche, Eisai, PharmaMar. B. Pineda Merlo: Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract